Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apyx Medical Corporation (APYX)
NASDAQ:APYX
Holding APYX?
Track your performance easily
APYX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.97 - $2.80
Previous Close$1.76
Volume11.95K
Average Volume (3M)54.07K
Market Cap
$62.49M
Enterprise Value$73.48M
Total Cash (Recent Filing)$28.01M
Total Debt (Recent Filing)$38.85M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Mar 13, 2025EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding34,643,886
10 Day Avg. Volume66,271
30 Day Avg. Volume54,071
Standard Deviation0.27
R-Squared0.06
Alpha-0.00667
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)5.51
Price to Sales (P/S)1.18
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.51
Enterprise Value/Gross Profit2.18
Enterprise Value/Ebitda-3.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering3
Apyx Medical News
PremiumCompany Announcements
Apyx Medical Reports Q3 Results and Restructuring
PremiumCompany Announcements
Apyx Medical’s Strategic Moves for Financial Stability
Bulls Say, Bears Say
Bulls Say
Market OpportunityBroader GLP-1 adoption could catalyze new demand for skin tightening treatments, positioning Apyx as one of the best companies to capitalize on this growing market.
Regulatory Approval And SafetyRenuvion's unique helium plasma technology is supported by over 90 clinical papers demonstrating its safety and efficacy, which has led to unique indications for use from the FDA.
Technology And Clinical InnovationRenuvion is viewed as a differentiated helium-based plasma technology that can save significant time and provide superior clinical outcomes in several large, high-growth plastic surgery markets.
Bears Say
Financial PerformanceApyx remains unprofitable and faces near-term financing challenges, which are expected to remain an overhang on shares.
Macroeconomic EnvironmentDemand for aesthetic capital equipment and procedures has contracted, reflecting a challenging macroeconomic environment.
Revenue And SalesTop-line guidance range was tweaked lower to reflect short-term macro headwinds impacting generator capital sales and an uptick in GLP use eating into procedure volume.
---
Ownership Overview
1.82% Insiders
10.48% Mutual Funds
24.43% Other Institutional Investors
59.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APYX FAQ
What was Apyx Medical Corporation’s price range in the past 12 months?
Apyx Medical Corporation lowest stock price was $0.97 and its highest was $2.80 in the past 12 months.
What is Apyx Medical Corporation’s market cap?
Currently, no data Available
When is Apyx Medical Corporation’s upcoming earnings report date?
Apyx Medical Corporation’s upcoming earnings report date is Mar 13, 2025 which is in 78 days.
How were Apyx Medical Corporation’s earnings last quarter?
Apyx Medical Corporation released its earnings results on Nov 08, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.184 by $0.044.
Is Apyx Medical Corporation overvalued?
According to Wall Street analysts Apyx Medical Corporation’s price is currently Overvalued.
Does Apyx Medical Corporation pay dividends?
Apyx Medical Corporation does not currently pay dividends.
What is Apyx Medical Corporation’s EPS estimate?
Apyx Medical Corporation’s EPS estimate is -$0.16.
How many shares outstanding does Apyx Medical Corporation have?
Apyx Medical Corporation has 37,643,887 shares outstanding.
What happened to Apyx Medical Corporation’s price movement after its last earnings report?
Apyx Medical Corporation reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.184. Following the earnings report the stock price went up 24.59%.
Which hedge fund is a major shareholder of Apyx Medical Corporation?
Among the largest hedge funds holding Apyx Medical Corporation’s share is Royce & Associates LLC. It holds Apyx Medical Corporation’s shares valued at 3M.
---
Apyx Medical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Increased
By 85.3K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.31%
12-Months-Change
Fundamentals
Return on Equity
-128.15%
Trailing 12-Months
Asset Growth
2.14%
Trailing 12-Months
Company Description
Apyx Medical Corporation
Apyx Medical Corp. operates as an energy-based medical technology company. It engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
---
APYX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strategic initiatives such as the development of the Ayon platform and restructuring efforts to streamline operations and extend financial runway. Despite these positive steps and growth in disposable and OEM segments, the company faced challenges with declining revenue and sales in their Advanced Energy segment, attributed to macroeconomic factors. The sentiment is mixed as the company is taking proactive measures but currently faces significant market challenges.Read More>---
APYX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering APYX
1 Year
1 Year Success Rate
8/25 ratings generated profit
1 Year Average Return
-18.08%
assigned a buy rating 2 months ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 32.00% of your transactions generating a profit, with an average return of -18.08% per trade.
---